Outer membrane vesicle vaccines.
Semin Immunol
; 50: 101433, 2020 08.
Article
en En
| MEDLINE
| ID: mdl-33309166
ABSTRACT
Outer Membrane Vesicles (OMV) have received increased attention in recent years as a vaccine platform against bacterial pathogens. OMV from Neisseria meningitidis serogroup B have been extensively explored. Following the success of the MeNZB OMV vaccine in controlling an outbreak of N. meningitidis B in New Zealand, additional research and development resulted in the licensure of the OMV-containing four-component 4CMenB vaccine, Bexsero. This provided broader protection against multiple meningococcal B strains. Advances in the field of genetic engineering have permitted further improvements in the platform resulting in increased yields, reduced endotoxicity and decoration with homologous and heterologous antigens to enhance immuno genicity and provide broader protection. The OMV vaccine platform has been extended to many other pathogens. In this review, we discuss progress in the development of the OMV vaccine delivery platform, highlighting successful applications, together with potential challenges and gaps.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Vacunas Bacterianas
/
Membrana Externa Bacteriana
/
Infecciones Meningocócicas
/
Neisseria meningitidis
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Semin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2020
Tipo del documento:
Article